Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16064343 | 0.84 | PYCR1 (0.41) | PYCR1SLC6A4HTR2AKCNH2KDR | |
| SCHEMBL17713492 | 0.81 | PYCR1 (0.39) | PYCR1 | |
| SCHEMBL17713491 | 0.78 | DPP4 (0.40) | PYCR1 | |
| SCHEMBL17713409 | 0.73 | TAAR1 (0.47) | HTR2A | |
| SCHEMBL32689207 | 0.72 | TAAR1 (0.52) | PYCR1HTR2A | |
| SCHEMBL1569794 | 0.72 | TAAR1 (0.52) | PYCR1HTR2A | |
| SCHEMBL17713426 | 0.72 | NAAA (0.36) | SLC6A4 | |
| SCHEMBL2551704 | 0.72 | PNMT (0.48) | PYCR1SLC6A4HTR2AKCNH2 | |
| SCHEMBL4573857 | 0.71 | PYCR1 (0.44) | PYCR1SLC6A4HTR2AKCNH2 | |
| Hydrochloric Acid SCHEMBL16760260 | 0.71 | TAAR1 (0.50) | PYCR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9901571-B2 | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20170304277-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-10-26 | — | — | US | disclosed |
| EP-3212648-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RaQualia Pharma Inc. (JP) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016067638-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304277-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | PYCR1 845/4885SLC6A4 1526/4885SLC6A2 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.